Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 83,132	$ 24,194
Marketable securities	11,005	27,802
Prepaid expenses and other assets	3,428	2,596
Total current assets	97,565	54,592
Property and equipment, net	7,379	8,628
Right of use assets – operating leases	1,664	4,822
Restricted cash	30	0
Deferred financing costs	146	4,111
Total assets	106,784	72,153
Current liabilities:
Accounts payable	2,409	1,728
Accrued expenses	7,026	10,361
Deferred revenue	1,185	2,459
Operating lease liabilities	856	3,437
Finance lease liabilities	532	1,162
Other current liabilities	943	523
Total current liabilities	12,951	19,670
Deferred revenue	45,000	45,000
Convertible promissory note	0	33,717
Derivative liability	0	5,739
Operating lease liabilities	891	976
Finance lease liabilities	468	872
Other long-term liabilities	1,176	1,041
Total liabilities	60,486	107,015
Commitments and contingencies (Note 5)
Convertible preferred stock	0	107,808
Stockholders’ equity (deficit):
Common stock $0.001 par value, 350,000,000 shares authorized, 40,304,436 and 2,217,737 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	40	2
Additional paid-in capital	270,029	1,197
Accumulated other comprehensive income (loss)	373	(41)
Accumulated deficit	(224,144)	(158,223)
Total Carisma Therapeutics Inc. stockholders’ equity (deficit)	46,298	(157,065)
Noncontrolling interests	0	14,395
Total stockholders’ equity (deficit)	46,298	(142,670)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 106,784	$ 72,153